Cogent Biosciences, Inc.
COGT
$34.04
-$0.33-0.96%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 63.58M | 51.34M | 48.77M | 45.49M | 43.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 333.36M | 307.60M | 299.66M | 288.47M | 275.94M |
| Operating Income | -333.36M | -307.60M | -299.66M | -288.47M | -275.94M |
| Income Before Tax | -328.94M | -294.37M | -284.08M | -269.50M | -255.86M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -328.94 | -294.37 | -284.08 | -269.50 | -255.86 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -328.94M | -294.37M | -284.08M | -269.50M | -255.86M |
| EBIT | -333.36M | -307.60M | -299.66M | -288.47M | -275.94M |
| EBITDA | -330.80M | -305.04M | -297.12M | -285.98M | -273.49M |
| EPS Basic | -2.55 | -2.48 | -2.53 | -2.48 | -721.35 |
| Normalized Basic EPS | -1.56 | -1.52 | -1.55 | -1.52 | -450.81 |
| EPS Diluted | -2.55 | -2.48 | -2.53 | -2.48 | -721.35 |
| Normalized Diluted EPS | -1.56 | -1.52 | -1.55 | -1.52 | -450.81 |
| Average Basic Shares Outstanding | 515.63M | 476.75M | 449.37M | 434.07M | 320.77M |
| Average Diluted Shares Outstanding | 515.63M | 476.75M | 449.37M | 434.07M | 320.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |